Nutrients最新文献

Background/objectives: Digestive problems are common in the general population and may be influenced by lifestyle, emotional status and diet. This study aimed to estimate the prevalence of digestive problems in Spanish adults and examined associated factors.

Methods: Descriptive cross-sectional analysis of anonymized adult microdata from the 2023 Spanish Health Survey was performed. Data were collected using a mixed-mode design (self-administered web questionnaire with interviewer-administered follow-up). Digestive problems were recoded by combining gastric ulcer, constipation, and prescribed use of laxatives, astringent drugs, and stomach medication. Therefore, digestive problems are primarily defined as the presence of gastric ulcers, diarrhea, and/or constipation. Variables included sociodemographic, Body Mass Index (BMI), smoking, alcohol intake, physical activity, Personal Health Questionnaire Depression Scale (PHQ-8), World Health Organization Well Being Index (WHO-5), and macronutrient intake estimated from a Food-Frequency Questionnaire using the Spanish Food Composition Database (BEDCA). Group comparisons and multivariable logistic regression were conducted (95% CI; significance level set at p < 0.05).

Results: Of 34,148 participants, 13,518 provided information on digestive problems; among these respondents, 3860 (28.6%) reported having digestive issues. Prevalence ranged from 5.2% to 36.5% among national territories. Higher odds (OR) of digestive problems were associated with age (OR 1.026, 95% CI 1.023-1.029), female sex (OR 1.168, 1.070-1.276), non-smoking (OR 1.240, 1.005-1.531) and ex-smoking (OR 1.447, 1.272-1.647) compared to current smokers, higher PHQ-8 scores (OR 1.040, 1.029-1.051), greater protein intake (OR 1.016, 1.009-1.023), consumption of sweet pastries (OR 1.058, 1.039-1.077), and dairy products (OR 1.027, 1.002-1.053); in contrast, lower odds were associated with higher WHO-5 scores (OR 0.985, 0.982-0.987), total fiber intake (OR 0.968, 0.949-0.987), and legume consumption (OR 0.894, 0.856-0.933).

Conclusions: Digestive problems show considerable variability in prevalence among survey-based Spanish sample. Digestive problems were associated with older age, female sex, depressive symptoms, high-protein intake, and higher consumption of sweet pastries and dairy products, whereas higher well-being scores, higher fiber intake and legume consumption were associated with lower odds of digestive problems.

Background: Deceptive caffeine ingestion has shown inconsistent effects as an ergogenic aid for short-term exercises. Objective: Therefore, the aim of this study was to evaluate the potential placebo effect of deceptive caffeine ingestion on short-term performance during countermovement and repeated-jump tests, as well as bench press throw and bench press-to-failure assessments, and to document any associated side effects. Methods: A repeated, randomized, and counterbalanced design was implemented to compare the effects of ingesting a placebo claimed to be caffeine with a control condition in which no substance was consumed. Twenty-five physically active young adults (17 men and 8 women) completed a countermovement jump (CMJ) test, a 15 s repeated-jump test, bench press throws at 25%, 50%, and 75% of 1RM, and a bench press-to-failure test at 75% of 1RM and also completed a questionnaire regarding potential side effects. Results: Performance was similar between the placebo and control in the CMJ (38.1 ± 6.8 vs. 37.5 ± 6.8 cm; p = 0.225; d = 0.25) and in the 15 s repeated-jump test (p > 0.05; trivial-small effects). In the bench press throw, propulsive mean velocity did not differ at 25% 1RM (p = 0.296; d = 0.23) or 50% 1RM (p = 0.626; d = 0.10). However, deceptive caffeine ingestion increased propulsive mean velocity at 75% 1RM (0.500 ± 0.131 vs. 0.480 ± 0.131 m/s; p = 0.024; d = 0.48) and increased repetitions to failure at the same load (11.9 ± 3.7 vs. 11.0 ± 3.1; p = 0.047; d = 0.42). Mean velocity during the first 3 repetitions tended to be higher with the placebo (p = 0.064; d = 0.39), while final repetitions were similar (p = 0.469; d = 0.15). The most common side effects were increased activeness (34.8%) and nervousness (17.4%). Conclusions: In summary, deceptive caffeine ingestion had minimal impact on jump and ballistic bench press performance in physically active individuals. However, repetitions to failure were improved by ≈1 repetition (+8.2%). These findings suggest that the placebo effect of caffeine is unlikely to serve as a reliable strategy for enhancing short-term exercise performance.

Lactobacilli strains are one of the major groups belonging to probiotics. Lactobacilli strains are known to be beneficial microbes widely studied and utilized for their health benefits and applications in various fields. Recently, Lactobacilli strains have emerged as promising agents in cancer management due to their ability to influence various physiological processes. Lactobacilli strains have shown potential in producing tumor-suppressive compounds, enhancing immune responses, and reshaping gut microbiota balance for the management of various cancer types. Lactobacilli strains demonstrated tumor-suppressive activity through mechanisms including induction of apoptosis, inhibition of migration, and regulation of key oncogenic signaling pathways. However, the effects of Lactobacilli strains appear to be strain- and cancer-type-dependent, necessitating further research to identify the most effective strains for the proper cancer type with the optimal treatment regimens. In this review article, we focus on Lactobacilli strains studied between 2021 and 2025 that have demonstrated tumor-suppressive properties in various experimental models. In addition, this article explores the current limitations in research methodologies and proposes potential avenues for future investigations in this area of study.

Background: The association between liver disease and gut microbiota is being widely investigated. Probiotics, such as Bacillus amyloliquefaciens, are among the most notable microbiomes examined in this study. Bacillus amyloliquefaciens shows potential for promoting growth and effectively regulating gut microbiota, though its mechanism of action remains unclear. Methods: The early gavage administration of Bacillus amyloliquefaciens BA5 conferred protection against liver injury in carbon tetrachloride (CCl₄)-induced mice. Growth parameters (body weight and organ index), serum biochemical markers (ALT, AST, T-SOD, MDA, GSH-Px, and T-AOC), liver and jejunum histopathology, and gut microbiota composition were comprehensively evaluated. Results: BA5 supplementation restored serum T-AOC, T-SOD, and GSH-Px levels and attenuated CCl₄-induced increases in ALT, AST, and MDA, suggesting potent anti-oxidant properties. Furthermore, histopathologic assessment showed that CCl₄-induced mice developed acute liver injury and intestinal villi were destroyed, while the BA5 group restored the pathological changes in the tissues to the normal group level. In addition, immunohistochemical staining revealed that BA5 increased the expression level of Claudin-1 which was a key biomarker for assessing the integrity of epithelial/endothelial barriers. Regarding gut microbiota, BA5 significantly enhanced the abundance of beneficial bacteria (Lactobacillus) and decreased the abundance of hazardous bacteria (Fusobacterium, Lachnoclostridium, Phascolarctobacterium, and Escherichia-shigella) caused by CCl₄. Notably, BA5 alone remarkably increased gut microbial diversity compared with that of the Control group. Conclusions: Overall, these findings suggest that BA5 holds promise as a potential therapeutic agent for alleviating CCl₄-induced acute liver injury in mice by mitigating oxidative stress and modulating gut microbiota.

Background/objectives: Vending machines in hospitals offer convenient access to snacks and beverages for employees, visitors, and patients. However, their contents are typically energy-dense and nutritionally poor, which can potentially reinforce unhealthy eating habits. This study aimed to evaluate the impact of introducing healthier vending machine options on purchasing behaviour and consumer perceptions in a hospital setting.

Methods: An interventional study was conducted at a university clinical centre in Slovenia. Sales data were collected from a standard vending machine and a pilot machine stocked with healthier products over two 14-day periods. Additionally, a consumer survey assessed factors influencing purchasing decisions and opinions on the healthier offerings.

Results: The proportion of healthy items purchased increased from 22% to 39% in the pilot vending machine, indicating a positive shift toward healthier choices. However, total sales declined by 18.81%, suggesting consumer hesitation toward the new product mix. Survey results identified price, ingredients, and visual appeal as the primary factors influencing purchase decisions.

Conclusions: The introduction of healthier vending machine options can promote better food choices in hospital environments, though challenges remain regarding consumer acceptance and sales performance. Expanding the variety of healthy items and adopting more competitive pricing strategies may enhance uptake. Further long-term research is needed to assess the sustainability of such interventions and their broader impact on hospital food environments.

Background/objectives: RELiZORB immobilized lipase cartridge (ILC) is a single-use digestive enzyme cartridge that connects in-line with enteral feeding circuits to hydrolyze triglycerides in enteral formulas. It is cleared by the FDA for pediatric and adult use. Limited data have been published regarding the effect of ILC use on growth in children younger than 5 years of age.

Methods: We performed a retrospective evaluation of real-world data extracted from a third-party reimbursement program database. All patients in the program database who initiated ILC use with enteral formula when 1 to 4 years of age between 2019 and 2023 were included. Baseline and follow-up weight, height/length, and body mass index (BMI) data were collected for up to 12 months.

Results: A total of 186 patients from 90 clinics in the United States were included. A subset (143 patients) with baseline and follow-up growth measurements was included in the efficacy analysis population; 76% were diagnosed with cystic fibrosis. Mean weight and BMI z-scores improved significantly (0.63 [p < 0.001] and 0.53 [p = 0.006], respectively) from baseline to 12 months after initiation of ILC use. Significant improvement in the mean weight z-score was observed after 3 months. Among people with cystic fibrosis (pwCF) who initiated ILC use when 2 to 4 years of age, those with a BMI ≥ 50th percentile increased from 22% at baseline to 43% after 12 months (p = 0.021). Improvement in weight-for-length was also observed in 1-year-old pwCF.

Conclusions: Real-world evidence showed that initiation of ILC use was associated with significant improvements in mean weight and BMI z-scores among young children.

Background: Postnatal growth failure in very preterm infants remains a major concern in neonatal care and clinical management is complicated by the lack of a standardized definition. This study aims to identify risk factors for growth faltering (GF) and undernutrition (UN) at hospital discharge, defined according to the latest consensus definitions established by the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN).

Methods: We conducted a retrospective observational study of 416 preterm infants (gestational age < 32 weeks and/or birth weight < 1500 g). Growth was monitored using the Intergrowth 21st standards. In line with ESPGHAN criteria, GF was defined longitudinally as a weight for age (WFA) z-score decline ≥ 1 SD from birth, while UN was defined cross-sectionally as a WFA or length for age z-score < -2 SD at discharge. Logistic regression models were used to determine independent predictors for both growth phenotypes.

Results: At discharge, the prevalence of GF and UN was 45.3% and 33.1%, respectively. In infants born without growth restriction (GR), UN was almost entirely driven by GF (89.7%). In contrast, 85.5% of infants born with GR remained undernourished at discharge. Multivariate analysis identified bronchopulmonary dysplasia and higher maximal postnatal weight loss as major independent risk factors for GF, while female sex and human milk feeding at discharge were associated with a lower risk of GF. For infants born with adequate weight, maternal hypertension, extremely low birth weight, and the co-occurrence of GF were the strongest predictors of UN.

Conclusions: Nearly half of very preterm infants experience significant growth impairment before discharge. By assessing the dynamic process of GF and the static endpoint of UN, we identified distinct clinical trajectories. Standardized ESPGHAN criteria allow for the identification of high-risk "phenotypes"-particularly those with GR at birth or severe neonatal morbidity-enabling more targeted and intensive nutritional management during the critical developmental window.

Objectives: We aimed to develop expert-informed recommendations for colleges and universities to support students with celiac disease (CeD) managing a gluten-free (GF) diet. Methods: A multidisciplinary panel of 40 stakeholders, including physicians, dietitians, a disability rights attorney, university staff, and students, was convened by the Celiac Disease Foundation to create expert-based and experience-informed recommendations. Over a 6-month period, the group conducted literature reviews, stakeholder interviews, and expert consensus discussions to identify common barriers and accommodations aligned with federal disability law. The expert panel collaboratively developed and revised an initial set of recommendations. Two rounds of structured voting were held during which panelists provided feedback to refine content and ensure clarity. All final recommendations were adopted with at least 90% of panelists voting in support. Results: The panel identified 24 accommodations across four domains: academics, housing, dining, and campus life. Academic recommendations include flexibility for illness-related absences, support for remote learning, and classroom modifications. Housing recommendations emphasize access to priority placement, appropriate appliances, and proximity to safe dining. Dining accommodations address GF food availability, ingredient transparency, staff training, and meal plan flexibility. Campus life recommendations ensure full participation in athletics, study abroad, social events, and internships, with supports for psychosocial well-being. Conclusions: This manuscript presents the first expert-informed recommendations focused specifically on the needs of college students with CeD. These recommendations are intended to support institutions as they develop strategies to enhance access to GF food, quality of life, educational supports, and student experience for those living with this chronic autoimmune condition.

Background: Population aging increases susceptibility to cognitive decline, anxiety, and metabolic dysregulation, yet safe and effective interventions remain limited. Saffron (Crocus sativus L.) has been traditionally used to enhance mood and cognition, and its main metabolites, crocins and safranal, exert neuroprotective, anxiolytic, and metabolic effects. However, variability in extract composition and frequent adulteration hinder reproducibility. Objectives: To clarify the efficacy of genuine saffron preparations in aging, we investigated a saffron extract standardized for safranal and crocin content (SSE). Methods: Safranal bioavailability was first characterized in rats, followed by an evaluation of behavioral, neuroendocrine, and metabolic outcomes after 35 days of oral SSE administration (25 or 200 mg/kg/day) in 25-month-old male C57BL/6 mice. Behavioral performance was assessed using open field and novel object recognition tests, while molecular analyses targeted neuropeptides in the hypothalamus and amygdala, hippocampal plasticity markers, cortical inflammatory proteins, and hepatic lipid metabolism genes. Results: SSE administration induced a rapid but transient increase in the plasma's safranal, confirming its bioavailability. In aged mice, the low dose prevented age-related weight loss and modulated hepatic lipid metabolism, whereas the high dose reduced anxiety-like behavior and improved recognition memory. The anxiolytic effects are consistent with elevated hypothalamic Npy, an anxiolytic peptide, reduced amygdalar Crh, a key mediator of stress and anxiety, and decreased hypothalamic Hcrt, an arousal modulator. The improvement in memory is associated with modulation of the cortical and hippocampal inflammatory and endocannabinoid proteins involved in neural plasticity. Conclusions: These findings highlight content-standardized saffron extracts as a promising multi-target nutraceuticals for healthy aging.

Background/Objectives: Caffeine is a well-established ergogenic aid in many strength- and endurance-based sports, but its efficacy in sport climbing remains underexplored despite the sport's unique physical demands on grip strength, power, and muscular endurance. Therefore, this study examined the acute impact of a low caffeine dose (3 mg/kg) on climbing-specific performance, including pull-up and grip tests, in intermediate-advanced climbers. Methods: In a triple-blind, randomized, crossover design, thirteen male climbers (age: 28.2 ± 8.6 years) completed two experimental trials (caffeine vs. placebo). Performance was assessed via a pull-up one-repetition maximum (1RM) and power test at various loads, a pull-up muscular endurance test, and grip tests including maximum dead-hang time, maximum dead-hang strength, and rate of force development (RFD). Results: Caffeine did not significantly enhance performance in any measured variable. While a non-significant increase in peak power was observed at 80% 1RM (+8.0%, 95% CI: -0.232 to 0.304, p > 0.05, g = 0.348), effects at other loads and on pull-up endurance were trivial based on effect size (e.g., repetitions: +3.3%, 95% CI: -3.30 to 4.37, p = 0.292, g = 0.061). For grip metrics, caffeine was associated with a modest reduction in endurance time (+7.4%, p = 0.162, g = 0.171) and a slight increase in maximum strength (+2.4%, p = 0.060, g = 0.120). RFD was unaffected (p > 0.169, g < 0.13). Despite the lack of objective improvement, participants reported significantly greater subjective feelings of strength, energy, and alertness with caffeine (p < 0.05). Conclusions: A 3 mg/kg dose of caffeine, while altering psycho-physiological state, did not elicit statistically or practically meaningful ergogenic effects on pull-up or grip performance in climbers. Higher doses or sport-specific performance tests should be investigated in future research.